Evidence map›Paper›PMID 24274894›Full record

ArticleBMC research notes2013

Prevalence of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae urinary isolates in a tertiary care hospital in Kathmandu, Nepal.

Anil Chander, Chandrika Devi Shrestha

Open access · goldAbstract read
In one paragraph

Article in BMC research notes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 101 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Detection of NDM Variants (Infection and drug resistance · 2022
    Article
  6. Carbapenem-ResistantInfection and drug resistance · 2022
    Article
  7. High prevalence of extended-spectrum beta-lactamase-producingFrontiers in cellular and infection microbiology · 2022
    Article
  8. Article
  9. Article
  10. Detection ofDiseases (Basel, Switzerland) · 2021
    Article
  11. Article
  12. Article
  13. Extended-Spectrum β-Lactamase-ProducingInfectious diseases · 2020
    Article
  14. Article
  15. Extended-SpectrumInterdisciplinary perspectives on infectious diseases · 2020
    Article
  16. Coexistence ofInternational journal of microbiology · 2019
    Article
  17. Article
  18. Article
  19. Distribution ofAntimicrobial resistance and infection control · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Anil ChanderDepartment of Microbiology, Kathmandu Medical College Teaching Hospital Sinamangal / Duwakot, Kathmandu, Nepal. dranilchander@yahoo.co.in.
Chandrika Devi Shrestha
Kathmandu Medical College Teaching Hospital · NP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEscherichia coli and Klebsiella pneumoniae are the major bacterial pathogens being isolated and reported from mid stream urine (MSU) specimens, globally. These uropathogens are mostly implicated as the major extended spectrum beta-lactamase (ESBL) producers, severely limiting the therapeutic management in cases of urinary tract infections. Limited studies had been reported from Nepal investigating the ESBL producers among uropathogens. This study was designed to assess the prevalence of ESBL producing E.coli and K. pneumoniae in urinary isolates at a centrally located major tertiary care hospital in Kathmandu valley, Nepal.

methodsBetween September 2011 and May 2012, during the nine months period, 6308 MSU specimens were collected aseptically from the same number of clinically suspected patients of urinary tract infections. The samples were cultured on MacConkey agar and blood agar. The isolates with significant bacteriuria (105 CFU / ml) were identified based on standard laboratory procedures. Antimicrobial susceptibility tests were carried out using various antimicrobial discs alongwith ceftriaxone on E.coli and K. pneumoniae isolates by Kirby Bauer disc diffusion method as per the recommendations of CLSI. On initial screening with ceftriaxone (30 μg) disc showing resistance was then confirmed for ESBL production by phenotypic confirmatory disc diffusion test (PCDDT) using ceftazidime (30 ug) and ceftazidime + clavulanic acid (30 μg + 10ug) disc as per guidelines of CLSI (2011).

resultsOut of a total of 6308 MSU specimens investigated for significant bacteriuria, E.coli isolates were 444 (7.04%) and K.pneuminiae were 145 (2.3%) making a total of 589 (9.34%). Initial screening with ceftriaxone disc revealed 155 isolates of E.coli and 70 isolates of K.pneumoniae to be resistant. Further testing by PCDDT method showed 60/444 (=13.51%) of E. coli and 24/145 (=16.55%) of K. pneumoniae isolates to be confirmed ESBL producers. These ESBL - producer uropathogens showed high degree of resistance to ceftriaxone (100.0%), amoxycillin, fluoroquinolones and co-trimoxazole.

conclusionAn emerging and moderately high prevalence of ESBL-producing E. coli and K. pneumoniae was observed and confirmed in the urinary isolates investigated. It is essential to have a regular and routine monitoring of ESBL producing clinical isolates in laboratory practice.

Indexed as

Tertiary Care CentersAdolescentAdultbeta-LactamasesEscherichia coliHumansKlebsiella pneumoniaeMicrobial Sensitivity TestsMiddle AgedNepalUrineYoung Adultbeta-Lactamases

Identifiers

PMID24274894
PMCPMC4222089
OpenAlexW2023257685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.